SCHEMBL2992436

SCHEMBL2992436

C=CCCC(c1ccccc1)P(=O)(O)O

nearest known ligand 0.60

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ACP3 P15309 8/20 0.60
SRC P12931 1/20 0.46
CYP2C19 P33261 1/20 0.42
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5293935 0.84 ACP3 (0.62) ACP3SRC
SCHEMBL9449512 0.82 ACP3 (0.58) ACP3SRCCYP2C19ALOX15TSHR
SCHEMBL11349187 0.78 ACP3 (0.68) ACP3SRC
SCHEMBL6545481 0.77 ACACB (0.41)
SCHEMBL10928799 0.77 ACP3 (0.66) ACP3SRC
SCHEMBL5198714 0.76 ACP3 (0.63) ACP3SRC
SCHEMBL3083466 0.76 CYP2C19 (0.39) ACP3SRCCYP2C19ALOX15TSHR
SCHEMBL7746269 0.75 ACP3 (0.68) ACP3SRC
SCHEMBL5035396 0.75 ACP3 (0.64) ACP3SRCCYP2C19TSHR
SCHEMBL1246417 0.74 ACP3 (0.62) ACP3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150132797-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING LIFE TECHNOLOGIES CORP (US) 2015-05-14 US claimed
US-20080038773-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US claimed
US-20080038772-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US claimed
US-20150132797-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING LIFE TECHNOLOGIES CORP (US) 2015-05-14 US disclosed
US-20100172861-A1 Anionic Polymers as Toxin Binders and Antibacterial Agents GENZYME CORPORATION (US) 2010-07-08 US disclosed
US-7678369-B2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2010-03-16 US disclosed
US-20080038773-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US disclosed
US-20080038772-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US disclosed
EP-1189622-B1 ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS GENZYME CORP (US) 2007-07-25 EP disclosed
EP-1800686-A2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2007-06-27 EP disclosed
EP-1800687-A2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2007-06-27 EP disclosed
US-20060029568-A1 Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents GENZYME CORPORATION (US) 2006-02-09 US disclosed
US-6890523-B2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2005-05-10 US disclosed
US-20030138397-A1 Anionic polymers as toxin binders and antibacterial agents GELTEX PHARMACEUTICALS, INC. 2003-07-24 US disclosed
US-6517827-B1 Polystyrene sulfonate polymer; Clostridium difficile GELTEX PHARMACEUTICALS, INC. 2003-02-11 US disclosed
US-6517826-B1 Polystyrene sulfonate polymer; Clostridium difficile GELTEX PHARMACEUTICALS, INC. 2003-02-11 US disclosed
EP-1189622-A2 ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS Geltex Pharmaceuticals, Inc. (US) 2002-03-27 EP disclosed
US-6290946-B1 ADMINISTERING TO THE ANIMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A POLYMER HAVING A PLURALITY OF PENDANT ACID FUNCTIONAL GROUPS WHICH ARE DIRECTLY ATTACHED TO THE POLYMER BACKBONE OR ATTACHED TO THE POLYMER BACKBONE BY A SPACER GROUP. GELTEX PHARMACEUTICALS, INC. 2001-09-18 US disclosed
WO-2000069428-A2 ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS GELTEX PHARMACEUTICALS, INC. (US) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100172861-A1 Anionic Polymers as Toxin Binders and Antibacterial Agents MSN, ANTXR2, PNKP ACP3 183/4885SRC 3822/4885CYP2C19 4744/4885
US-20060029568-A1 Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents DDOST, DNPEP, IDUA ACP3 72/4885SRC 3302/4885CYP2C19 4413/4885
US-20030138397-A1 Anionic polymers as toxin binders and antibacterial agents MSN, ANTXR2, PNKP ACP3 183/4885SRC 3822/4885CYP2C19 4744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.